Look at Comprehensive Prescribing Facts OPDIVO® (nivolumab) is indicated for your treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed soon after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or soon after 3